SYRS (Syros Pharmaceuticals Inc.) Yalpi foyda bo'yicha rentabellik

Syros Pharmaceuticals Inc. (SYRS) korporativ emblemasi va logotipi

Syros Pharmaceuticals (SYRS) yuqori operatsion barqarorlikni ta'minlash uchun DNK terapiyasi uchun xomashyo ta'minot zanjirlarini optimallashtirmoqda. Biznesni rivojlantirish ventura investitsiyalariga va klinik gipotezalarning muvaffaqiyatiga tayanadi. Portfelga 2026-yilga borib bozorga kirishi kutilayotgan leykozga qarshi davolash vositalari kiradi. 0.00 qiymati joriy parametr holatini belgilaydi, bu esa yalpi foyda marjasining taqsimlanishini aniq ko'rsatadi.

Yalpi foyda bo'yicha rentabellik: Syros Pharmaceuticals (SYRS) 04.07.2022 - 29.03.2025 uchun

syros.com (SYRS) moliyaviy va bozor koʻrsatkichlari kesimi

- bozor qiymati va tahlilchilarning maqsadli prognozi:
- biznesning bozor baholash ko'rsatkichlari:
Syros Pharmaceuticals yetakchi tovari

Hozirda gematologiya dori vositalarini faol ishlab chiqish bosqichida bo'lgan Syros Pharmaceuticals (SYRS) uchun yalpi foyda marjasi bevosita xarajatlarni boshqarish samaradorligining asosiy ko'rsatkichi bo'lib xizmat qiladi. Ushbu yalpi rentabellik grafigini tahlil qilish orqali investor sotilgan tovarlar tannarxi chegirib tashlanganidan keyin qolgan daromad qismini ko'rishi mumkin. Ushbu ko'rsatkichning barqarorligi kompaniyaning 2026-yilda bozorga kirganidan keyin genlar ekspressiyasidagi innovatsiyalarni monetizatsiya qilish qobiliyatini tasdiqlaydi.

Toʻgʻridan-toʻgʻri raqobatchilar

Yalpi foyda bo'yicha rentabellik Tempus AI Inc|QGEN (Qiagen NV) - Yalpi marja|Yalpi foyda bo'yicha rentabellik Ionis Pharma (IONS)|Yalpi rentabellik Repligen Corp (RGEN)|RNA - Yalpi foyda marjasi|crisprtx.com - Yalpi foyda bo'yicha rentabellik|Yalpi foyda normasi WGS|RARE - Yalpi rentabellik|Beam Tx (BEAM) - Yalpi foyda bo'yicha rentabellik|SRPT (Sarepta Therapeutics Inc) - Yalpi foyda bo'yicha rentabellik|TWST: Yalpi foyda koeffitsiyenti|TXG (10xgenomics.com) - Yalpi marja|NTLA (Intellia Therapeutics, Inc.) - Yalpi foyda koeffitsiyenti|Yalpi rentabellik Stoke Corp (STOK)|Yalpi foyda bo'yicha sotuv rentabelligi BioLife|Yalpi marja WVE (Wave Life Sciences Ltd)|MAZE: Sotuvning yalpi rentabelligi|Sionna Therapeutics, Inc. - Yalpi marja|Yalpi foyda normasi PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Yalpi foyda bo'yicha rentabellik|QURE - Yalpi foyda bo'yicha sotuv rentabelligi|MGTX (MeiraGTx Corp) - Yalpi marja|Yalpi foyda marjasi REGENXBIO Inc. RGNX|Yalpi rentabellik Solid Biosciences (SLDB)|Ocugen Corp - Sotuvning yalpi rentabelligi|Yalpi rentabellik Pacific Biosciences PACB|Yalpi foyda koeffitsiyenti BNTC (Benitec)|Design Corp - Yalpi marja|Rocket Pharmaceuticals - Yalpi foyda koeffitsiyenti|Sotuvning yalpi rentabelligi 4D Molecular Therapeutics, Inc.|Yalpi foyda marjasi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Yalpi marja|Yalpi foyda marjasi Editas EDIT|Yalpi marja SLN|ProQR Therapeutics - Sotuvning yalpi rentabelligi|Yalpi marja CDXS (Codexis, Inc.)|SGMO: Sotuvning yalpi rentabelligi|Nautilus Biotechnology - Yalpi marja|Yalpi foyda normasi MGX (Metagenomi, Inc)|DTIL: Yalpi marja|GBIO: Yalpi foyda koeffitsiyenti|Yalpi rentabellik Boundless Bio Inc.|Yalpi foyda bo'yicha rentabellik Exicure (XCUR)|Yalpi marja IMNN|PHIO (Phio Pharmaceuticals Corp.) - Yalpi foyda normasi|Mustang Bio, Inc. - Yalpi foyda bo'yicha rentabellik|RNAZ - Yalpi foyda bo'yicha rentabellik|BNGO: Yalpi foyda bo'yicha rentabellik|APDN (Applied DNA Sciences Inc) - Sotuvning yalpi rentabelligi|BLUE (Bluebird Bio) - Yalpi foyda bo'yicha rentabellik|ImmunoPrecise Antibodies Ltd - Yalpi foyda normasi|OMGA (Omega Therapeutics Inc) - Yalpi marja|Yalpi rentabellik OMIC|Yalpi rentabellik Regulus Therapeutics Inc. (RGLS)|Yalpi foyda bo'yicha sotuv rentabelligi Codex DNA|Yalpi rentabellik TRACON TCON|Unity Biotechnology, Inc - Yalpi rentabellik